Drugs Containing Excipient (Inactive Ingredient) CYANOCOBALAMIN

Generic drugs containing CYANOCOBALAMIN excipient

Company	Ingredient	NDC	Excipient
Shenzhen Tianzhu Fragrance Co Ltd	minoxidil 5%	82987-201	CYANOCOBALAMIN
Abeona Therapeutics Inc	prademagene zamikeracel	84103-007	CYANOCOBALAMIN

Cyanocobalamin Pharmaceutical Market Dynamics and Financial Trajectory

Last updated: September 5, 2026

Cyanocobalamin is a mature, low-cost form of vitamin B12 used primarily as an active pharmaceutical ingredient, nutritional ingredient, and supplement component rather than as a conventional excipient. Its commercial outlook is stable to moderately positive in volume, but weak in pricing power. Growth is driven by dietary supplements, fortified foods, injectable deficiency treatment, bariatric-care demand, and expanding consumer use of high-dose B12 products. The market has limited patent protection, substantial generic competition, and relatively low barriers to formulation once a compliant supply source is qualified.

Is cyanocobalamin an excipient or an active pharmaceutical ingredient?

Cyanocobalamin is generally classified as an active ingredient, not an excipient.

The compound is a synthetic form of vitamin B12. It is used to prevent or treat vitamin B12 deficiency, including deficiency associated with pernicious anemia, malabsorption, restrictive diets, gastrointestinal surgery, and certain drug exposures. U.S. product labels identify cyanocobalamin as the active ingredient in tablets, oral solutions, nasal products, and injectable medicines (U.S. National Library of Medicine, 2024a, 2024b).

An excipient is an inactive component used to support manufacturing, stability, delivery, taste, appearance, or dosage-form performance. Cyanocobalamin can appear in products alongside conventional excipients such as lactose, microcrystalline cellulose, starch, magnesium stearate, preservatives, and water for injection. Its therapeutic role remains active, however.

Classification	Commercial role
Active pharmaceutical ingredient	Vitamin B12 replacement and deficiency treatment
Nutraceutical ingredient	Supplements, multivitamins, gummies, lozenges, and fortified beverages
Food ingredient	Fortified cereals, plant-based beverages, meal replacements, and nutritional products
Conventional excipient	Limited and generally not the primary commercial classification
Biological product	No. Cyanocobalamin is a small-molecule vitamin, not a biologic

This classification matters for market analysis. Cyanocobalamin demand is tied to therapeutic and nutritional consumption rather than to the broader excipient market, which is dominated by materials such as binders, fillers, coatings, preservatives, solubilizers, and controlled-release polymers.

What drives demand for cyanocobalamin?

Demand is divided between pharmaceutical treatment, consumer supplements, and food fortification.

Pharmaceutical demand

Prescription and over-the-counter pharmaceutical demand is concentrated in:

• Injectable cyanocobalamin for confirmed deficiency and malabsorption
• Oral tablets and sublingual products
• Nasal formulations
• Multivitamin and mineral products
• Products used in post-bariatric surgery care
• Medical nutrition and elderly-care products

Injectable products have higher manufacturing and regulatory requirements than tablets, but the active ingredient cost is still a small portion of total product cost. Sterility, container closure, fill-finish capacity, quality testing, and distribution conditions usually have greater economic significance than the cyanocobalamin powder itself.

Supplement demand

Supplement demand is broader and more price-sensitive. Cyanocobalamin competes with methylcobalamin, adenosylcobalamin, and combination vitamin B products. Cyanocobalamin remains attractive to manufacturers because it has a long history of use, broad regulatory familiarity, strong stability characteristics, and low raw-material cost.

Consumer products often use marketing claims around energy, nerve function, vegetarian and vegan diets, and general wellness. These claims support unit growth but do not create meaningful ingredient-level pricing power.

Food fortification

Food fortification provides recurring, high-volume demand. Cyanocobalamin is used in fortified cereals, dairy alternatives, nutritional drinks, meal replacements, and specialized medical foods. The dosage per unit is low, so the market is volume-driven and sensitive to raw-material procurement, premix formulation, and regulatory specifications.

The National Institutes of Health identifies cyanocobalamin as one of the common supplemental forms of vitamin B12 and notes that absorption and clinical use depend on the product form and patient condition (National Institutes of Health, Office of Dietary Supplements, 2024).

How large is the cyanocobalamin market?

There is no authoritative public market dataset that isolates cyanocobalamin as a standalone excipient market. Published market reports typically aggregate vitamin B12, vitamin ingredients, nutraceuticals, pharmaceutical excipients, or specialty nutrition products. Those categories are not interchangeable.

A defensible market assessment therefore uses demand proxies rather than a single market-size estimate.

Market proxy	Direction	Financial implication
Vitamin B12 supplements	Growing	Supports higher unit demand and product launches
Injectable deficiency treatment	Stable to modest growth	Provides recurring pharmaceutical demand
Food fortification	Stable growth	Produces large but low-margin ingredient volumes
Premium methylcobalamin products	Growing from a smaller base	Creates formulation substitution risk
Cyanocobalamin API pricing	Flat to declining	Limits supplier margin expansion
Sterile injectable manufacturing	Capacity constrained in some regions	Raises finished-product value more than API value
Regulatory-quality requirements	Rising	Favors qualified suppliers with documentation and audit history

The market is financially attractive at the finished-product and branded-supplement level, but less attractive at the bulk cyanocobalamin ingredient level. Suppliers compete primarily through manufacturing scale, specification compliance, consistency, documentation, delivery reliability, and price.

What is the financial trajectory for cyanocobalamin?

The expected trajectory is low-to-mid single-digit volume growth with flat or declining real pricing for standard-grade material. Revenue growth should be stronger in consumer supplements and fortified nutrition than in mature pharmaceutical products.

Base-case trajectory

The base case has four characteristics:

1. Demand expands gradually through supplement use, aging populations, plant-based diets, and nutrition products.
2. Standard cyanocobalamin pricing remains under pressure from multiple qualified suppliers.
3. Finished-dose manufacturers capture more value than bulk ingredient producers.
4. Premium formats and differentiated delivery systems grow faster than unbranded powder.

Upside factors

Upside may come from:

• Increased diagnosis and treatment of vitamin B12 deficiency
• More supplementation among older adults
• Growth in vegan and vegetarian nutrition
• Expansion of fortified plant-based foods
• Bariatric surgery follow-up protocols
• New oral, sublingual, nasal, or extended-release products
• Supply-chain diversification away from concentrated manufacturing regions
• Customer preference for pharmaceutical-grade documentation and traceability

Downside factors

Downside risks include:

• Substitution by methylcobalamin or combination B12 products
• Weak pricing due to commoditization
• Excess global manufacturing capacity
• Lower consumer spending on supplements
• Retailer private-label competition
• Product recalls involving assay, contamination, or labeling
• Regulatory restrictions on health claims
• Concentration of demand in low-dose products

The most likely financial result is modest revenue growth without sustained expansion in bulk ingredient margins. Companies with finished-dose brands, sterile fill-finish operations, or integrated vitamin premix platforms are better positioned than suppliers selling only commodity cyanocobalamin.

Which companies supply or manufacture cyanocobalamin?

The supply chain includes vitamin manufacturers, pharmaceutical API producers, contract manufacturers, premix companies, and supplement manufacturers. Public disclosures rarely report cyanocobalamin revenue separately.

Relevant supplier categories include:

Supplier category	Competitive advantage
Large vitamin and nutrition companies	Scale, premix capability, global distribution
Pharmaceutical API manufacturers	GMP documentation, regulatory support, batch consistency
Contract development and manufacturing organizations	Formulation, encapsulation, tableting, sterile fill-finish
Supplement manufacturers	Brand access and rapid product commercialization
Specialty nutrition companies	Medical-food and fortified-product relationships

The commercial buyer typically evaluates:

• Assay and impurity profile
• Microbiological quality
• Residual solvents and elemental impurities
• Particle size and blend uniformity
• Stability under light and heat exposure
• GMP status
• DMF or equivalent regulatory support
• Country of origin and supply continuity
• Batch-release documentation
• Change-control procedures

Cyanocobalamin is light-sensitive and can require controlled storage and packaging. Finished-product manufacturers may use opaque containers, protective packaging, or validated light-exposure controls depending on dosage form and formulation.

What patents protect cyanocobalamin products?

The core cyanocobalamin molecule is not protected by an enforceable composition-of-matter patent in the United States. It is a long-established vitamin with a mature generic supply base.

Patent protection may still apply to:

• Specific dosage forms
• Nasal delivery systems
• Sublingual or orally disintegrating formulations
• Combination products
• Sustained-release systems
• Device components
• Manufacturing or purification processes
• Particular methods of treating deficiency
• Product packaging or stability systems

These rights generally protect a finished product or process, not cyanocobalamin as a molecule.

IP category	Current strategic importance
Core molecule patent	None of practical commercial significance
API manufacturing patents	Potentially relevant to cost and qualification
Tablet and capsule formulation patents	Usually limited and easy to design around
Injectable formulation patents	More relevant because of sterility and stability requirements
Nasal delivery patents	Potentially material for branded products
Method-of-use patents	Narrow unless tied to a specific patient population or regimen
Device patents	Relevant to nasal and self-administration systems
Trade secrets	Important for yield, purification, and process economics

Patent searches should distinguish cyanocobalamin from cobalamin derivatives. A patent claiming methylcobalamin, hydroxocobalamin, or adenosylcobalamin does not necessarily cover cyanocobalamin.

What is the Orange Book status of cyanocobalamin?

The FDA Orange Book does not list cyanocobalamin as a standalone ingredient category. It lists approved drug products and their therapeutic-equivalence information. Cyanocobalamin products may appear through individual approved drug applications, but the ingredient itself does not receive an independent Orange Book exclusivity period.

The commercial implications are straightforward:

• No active new chemical entity exclusivity is associated with the mature molecule.
• Generic competition is permitted where approved products meet FDA requirements.
• Patent listings, if any, attach to specific approved products.
• Nutritional supplements generally fall outside the prescription-drug Orange Book framework.
• Injectable products must meet drug-quality and manufacturing requirements but do not receive molecule-level exclusivity.

FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations is the relevant reference for approved prescription and over-the-counter drug products, patent certifications, and therapeutic-equivalence information (U.S. Food and Drug Administration, 2024a).

When does cyanocobalamin lose exclusivity?

Cyanocobalamin has already lost molecule-level exclusivity in the United States and other major pharmaceutical markets. Commercial exclusivity now depends on product-specific patents, regulatory status, brand recognition, supply contracts, and manufacturing approvals.

Paragraph IV challenges

Paragraph IV litigation is relevant only when a generic applicant challenges a listed patent covering a particular cyanocobalamin drug product. It is not a mechanism for challenging the bulk ingredient itself.

Risk is highest where a branded product has:

• A differentiated delivery device
• A patented nasal or oral formulation
• A combination of cyanocobalamin with another active ingredient
• A narrow method-of-use patent
• A commercially important product with strong prescription sales

Risk is lower for conventional tablets, capsules, and standard injectable products with no meaningful formulation protection.

Settlement agreements

Settlement agreements may arise for branded delivery systems or combination products, but they are not a defining feature of the bulk cyanocobalamin market. In a mature vitamin market, commercial settlements are more likely to concern a particular dosage form than the underlying active ingredient.

What regulatory requirements affect cyanocobalamin manufacturers?

Cyanocobalamin manufacturers must align the product with its intended regulatory use.

Pharmaceutical API

Pharmaceutical-grade material generally requires:

• GMP manufacturing
• Validated analytical methods
• Impurity and degradation controls
• Stability data
• Supplier qualification
• Batch traceability
• Change-control systems
• Regulatory support documentation
• Compliance with applicable pharmacopoeial standards

The USP-NF includes standards for vitamin-related pharmaceutical materials and dosage forms, while national authorities may apply additional requirements based on route of administration and product category (United States Pharmacopeia, 2024).

Supplements and food

Food and supplement products are subject to different rules from approved drugs. In the United States, dietary supplements are regulated under the Federal Food, Drug, and Cosmetic Act and the Dietary Supplement Health and Education Act. Manufacturers must control identity, purity, strength, composition, and contamination risks, while disease-treatment claims can trigger drug regulation (U.S. Food and Drug Administration, 2023).

Injectable products

Injectables carry the highest operational burden. Manufacturers must control:

• Sterility
• Endotoxins
• Particulate matter
• Container closure integrity
• Preservative concentration where applicable
• Assay and degradation products
• Aseptic processing or terminal sterilization strategy

These controls create a manufacturing barrier that is more significant than any remaining cyanocobalamin molecule patent.

How does cyanocobalamin compare with methylcobalamin?

Cyanocobalamin has the broadest cost and regulatory base. Methylcobalamin is often positioned as a premium alternative in supplements and certain clinical markets.

Attribute	Cyanocobalamin	Methylcobalamin
Market maturity	Very high	High, but more premium-oriented
Raw-material economics	Generally lower cost	Generally higher cost
Regulatory familiarity	Extensive	Extensive but product-specific
Stability profile	Strong commercial history	Formulation-dependent
Consumer positioning	Mainstream and economical	Premium and “active-form” positioning
Patent risk	Low at molecule level	Low at molecule level, with formulation-specific exceptions
Substitution risk	Can lose share in premium supplements	Can capture share from standard products

Marketing claims about superior absorption or clinical performance require careful review. Consumer positioning can shift market share without creating a durable patent moat.

What generic launch risks exist for cyanocobalamin products?

Generic launch risk is high for standard oral products and moderate for injectables.

Product type	Generic-entry risk	Primary barrier
Standard tablet	High	Bioequivalence and manufacturing compliance
Capsule	High	Formulation equivalence
Oral solution	High to moderate	Stability, dosing accuracy, preservative system
Sublingual tablet	Moderate	Performance and formulation differentiation
Nasal spray	Moderate	Device, delivery, and clinical requirements
Injectable vial	Moderate	Sterility, fill-finish, and supply qualification
Prefilled syringe	Lower	Device and container-closure complexity
Combination product	Moderate	Product-specific formulation and patent scope

For bulk cyanocobalamin, the key risk is supplier competition rather than generic launch litigation. A customer can qualify an alternative manufacturer if the replacement meets quality, regulatory, and supply requirements.

What manufacturing and intellectual-property barriers protect suppliers?

The principal barriers are operational rather than patent-based.

Manufacturing barriers

• Consistent high-purity production
• Control of light-sensitive material
• Reproducible assay and impurity performance
• Scalable crystallization and purification
• Reliable raw-material sourcing
• Regulatory audit history
• Qualification by major pharmaceutical and nutrition customers

Intellectual-property barriers

Process patents and trade secrets may improve yield, reduce waste, or control impurity formation. These rights can support a cost advantage, but they rarely prevent market entry if competitors can use alternative processes.

For buyers, regulatory qualification creates switching costs. Even when multiple suppliers exist, a pharmaceutical customer may avoid changing sources because a change can require stability work, validation, regulatory notifications, and new supplier audits.

What revenue exposure exists for pharmaceutical companies?

Cyanocobalamin is unlikely to be a material revenue driver for diversified pharmaceutical companies. Its economic importance is greater for:

• Vitamin manufacturers
• Supplement brands
• Medical-nutrition companies
• Generic injectable manufacturers
• Contract manufacturers
• Premix suppliers
• Specialty API distributors

Revenue exposure should be assessed through product-level sales rather than corporate revenue. A company may have meaningful cyanocobalamin volume but limited profit contribution because the ingredient is inexpensive and highly substitutable.

The highest-value commercial positions are usually:

1. Branded finished products with consumer recognition
2. Premium delivery systems
3. Sterile injectable manufacturing
4. Integrated vitamin premix platforms
5. Long-term supply contracts with regulated customers

Key Takeaways

• Cyanocobalamin is primarily an active pharmaceutical and nutritional ingredient, not a conventional excipient.
• Molecule-level patent protection has expired, leaving a mature and competitive market.
• Demand should grow gradually through supplements, food fortification, aging-related deficiency treatment, and bariatric-care products.
• Bulk ingredient pricing is likely to remain flat or decline in real terms.
• Finished-dose products, sterile injectables, branded supplements, and premium delivery systems capture more value than commodity API sales.
• Paragraph IV litigation, Orange Book listings, and settlement activity are product-specific rather than ingredient-wide.
• The main barriers are GMP compliance, sterility, quality documentation, supplier qualification, process know-how, and customer switching costs.
• Methylcobalamin is the main substitution and premium-positioning threat, particularly in consumer supplements.
• Financial upside is stronger for integrated manufacturers and branded product owners than for undifferentiated cyanocobalamin suppliers.

FAQs

Is cyanocobalamin approved by the FDA?

Yes. Cyanocobalamin is used in FDA-regulated drug products, including injectable, oral, and other dosage forms. It is also used in dietary supplements and fortified foods under separate regulatory frameworks.

Does cyanocobalamin have a patent?

The cyanocobalamin molecule is not covered by a commercially significant active composition patent. Product-specific patents may cover delivery systems, formulations, devices, combinations, or manufacturing processes.

Is cyanocobalamin cheaper than methylcobalamin?

Cyanocobalamin is generally positioned as the lower-cost and more established form. Actual pricing depends on grade, dosage form, supplier qualification, packaging, and purchase volume.

Can cyanocobalamin be used in injectable products?

Yes. Injectable cyanocobalamin products are established pharmaceutical products. Sterility, endotoxin, particulate, stability, and container-closure controls are central manufacturing requirements.

Is cyanocobalamin a good investment market?

The ingredient market is defensive but commoditized. Investment quality is stronger in branded supplements, sterile manufacturing, medical nutrition, and integrated supply platforms than in undifferentiated bulk cyanocobalamin production.

References

1. National Institutes of Health, Office of Dietary Supplements. (2024). Vitamin B12 fact sheet for health professionals. https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/

2. U.S. Food and Drug Administration. (2023). Dietary supplements. https://www.fda.gov/food/dietary-supplements

3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

4. U.S. National Library of Medicine. (2024a). Cyanocobalamin injection: Drug label information. DailyMed. https://dailymed.nlm.nih.gov/

5. U.S. National Library of Medicine. (2024b). Cyanocobalamin tablet: Drug label information. DailyMed. https://dailymed.nlm.nih.gov/

6. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.